Osteoimmunology: Influence of the Immune System on Bone Regeneration and Consumption

Abstract

Background Stimulating bone regeneration is a central aim in orthopaedic and trauma surgery. Although the replacement of bone with artificial materials like cement or apatite helps to keep up bone stability, new bone often cannot be regenerated. Increasing research efforts have led to the clinical application of growth factors stimulating bone growth (e.g. bone morphogenic protein, BMP) and inhibitors preventing bone consumption (e.g. RANKL blocking antibodies). These factors mostly concentrate on stimulating osteoblast or preventing osteoclast activity.

Current Situation It is widely accepted that osteoblasts and osteoclasts are central players in bone regeneration. This concept assumes that osteoblasts are responsible for bone growth while osteoclasts cause bone consumption by secreting matrix-degrading enzymes such as cathepsin K and matrix metalloproteinases (MMP). However, according to new research results, bone growth or consumption are not regulated by single cell types. It is rather the interaction of various cell types that regulates bone metabolism. While factors secreted by osteoblasts are essential for osteoclast differentiation and activation, factors secreted by activated osteoclasts are essential for osteoblast activity. In addition, recent research results imply that the influence of the immune system on bone metabolism has long been neglected. Factors secreted by macrophages or T cells strongly influence bone growth or degradation, depending on the bone microenvironment. Infections, sterile inflammation or tumour metastases not only affect bone cells directly, but also influence immune cells such as T cells indirectly. Furthermore, immune cells and bone are mechanistically regulated by similar factors such as cytokines, chemokines and transcription factors, suggesting that the definition of bone and immune cells has to be thought over.

Outlook Bone and the immune system are regulated by similar mechanisms. These newly identified similarities between bone and the immune system imply that medication developed for tumour and autoimmune patients could also be applied in bone diseases.

Key words

osteoimmunology - osteoblast - osteoclast - bone regeneration

• References/Literatur

• 1 Danks L, Takayanagi H. Immunology and bone. J Biochem 2013; 154: 29-39
• 2 Fujita K, Iwasaki M, Ochi H. et al. Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med 2012; 18: 589-594
• 3 Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304
• 4 Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5: 667-676
• 5 Takayanagi H, Kim S, Matsuo K. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416: 744-749
• 6 Akiyama T, Shinzawa M, Akiyama N. RANKL-RANK interaction in immune regulatory systems. World J Orthop 2012; 3: 142-150
• 7 Takeda S. Central control of bone remodelling. J Neuroendocrinol 2008; 20: 802-807
• 8 Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol 2014; 5: 511
• 9 Takayanagi H. New immune connections in osteoclast formation. Ann N Y Acad Sci 2010; 1192: 117-123
• 10 Takayanagi H. Osteoimmunology in 2014: Two-faced immunology – from osteogenesis to bone resorption. Nat Rev Rheumatol 2015; 11: 74-76
• 11 Guihard P, Danger Y, Brounais B. et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012; 30: 762-772
• 12 Charles JF, Aliprantis AO. Osteoclasts: more than ʼbone eatersʼ. Trends Mol Med 2014; 20: 449-459
• 13 Nicolaidou V, Wong MM, Redpath AN. et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012; 7: e39871
• 14 Fernandes TJ, Hodge JM, Singh PP. et al. Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner. PLoS One 2013; 8: e73266
• 15 Walker EC, McGregor NE, Poulton IJ. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 2010; 120: 582-592
• 16 Sims NA, Quinn JM. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. Bonekey Rep 2014; 3: 527
• 17 Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol 2012; 8: 684-689
• 18 Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295
• 19 Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015; 16: 343-353
• 20 Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev 2011; 241: 133-144
• 21 Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014; 35: 51-60
• 22 Sacher T, Knolle P, Nichterlein T. et al. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol 2002; 32: 3628-3637
• 23 Limmer A, Ganss R, Garbi N. et al. Stimulation of autoimmunity by toll-like receptor ligands. Ann Rheum Dis 2005; 64 (Suppl. 04) iv15-iv17
• 24 Zhang Q, Vignali DA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity 2016; 44: 1034-1051
• 25 Takayanagi H. SnapShot: osteoimmunology. Cell Metab 2015; 21: 502.e1
• 26 Kong YY, Yoshida H, Sarosi I. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323
• 27 Feuerer M, Beckhove P, Garbi N. et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9: 1151-1157
• 28 Mendez-Ferrer S, Michurina TV, Ferraro F. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834
• 29 Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 2011; 208: 421-428
• 30 Winkler IG, Sims NA, Pettit AR. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010; 116: 4815-4828
• 31 Chow A, Lucas D, Hidalgo A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011; 208: 261-271
• 32 Shaw JP, Utz PJ, Durand DB. et al. Identification of a putative regulator of early T cell activation genes. Science. 1988. 241: 202–205. J Immunol 2010; 185: 4972-4975
• 33 Pan M, Winslow MM, Chen L. et al. Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. J Immunol 2007; 178: 4315-4321
• 34 Martinez GJ, Pereira RM, Aijo T. et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity 2015; 42: 265-278
• 35 Winslow MM, Pan M, Starbuck M. et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 2006; 10: 771-782
• 36 Shane E, Rodino MA, McMahon DJ. et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998; 17: 1089-1096
• 37 Takayanagi H, Ogasawara K, Hida S. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600-605
• 38 Yasuda H, Shima N, Nakagawa N. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602
• 39 Wong BR, Rho J, Arron J. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272: 25190-25194
• 40 Anderson DM, Maraskovsky E, Billingsley WL. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179
• 41 Loser K, Mehling A, Loeser S. et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-1379
• 42 Sakaguchi S, Miyara M, Costantino CM. et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500
• 43 Roodman GD, Ibbotson KJ, MacDonald BR. et al. 1,25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci U S A 1985; 82: 8213-8217
• 44 Kikuta J, Kawamura S, Okiji F. et al. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A 2013; 110: 7009-7013
• 45 Ishii M, Egen JG, Klauschen F. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009; 458: 524-528
• 46 Chi H. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 2011; 32: 16-24
• 47 Aoki M, Aoki H, Ramanathan R. et al. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016; 2016: 8606878
• 48 Okamoto H, Takuwa N, Yokomizo T. et al. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol 2000; 20: 9247-9261
• 49 Lotinun S, Kiviranta R, Matsubara T. et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013; 123: 666-681
• 50 Jordan KR, McMahan RH, Kemmler CB. et al. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A 2010; 107: 4652-4657
• 51 Jordan MB, van Rooijen N, Izui S. et al. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 2003; 101: 594-601